These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 21242747

  • 41. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A, Elisei W, Brandimarte G, Giorgetti G, Penna A, Castrignano V.
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 44. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
    Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF.
    Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Management of Crohn's disease of the ileoanal pouch with infliximab.
    Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ.
    Am J Gastroenterol; 2003 Oct; 98(10):2239-44. PubMed ID: 14572574
    [Abstract] [Full Text] [Related]

  • 47. Induction of pustular lesions during infliximab therapy for Crohn's disease.
    Pérez-Pérez L, Caeiro JL, Fabeiro JM, Allegue F, Zulaica A.
    Acta Derm Venereol; 2008 Oct; 88(3):292-3. PubMed ID: 18480940
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Oct; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

  • 50. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.
    Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, Johanns J, Lang Y, Markowitz J, Cohen S, Winter HS, Veereman-Wauters G, Ferry G, Baldassano R.
    Curr Med Res Opin; 2011 Mar; 27(3):651-62. PubMed ID: 21241207
    [Abstract] [Full Text] [Related]

  • 51. Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed.
    Menachem Y, Avidan B, Lavy A, Lang A, Bardan E, Fidder H, Bar-Meir S, Chowers Y.
    Digestion; 2005 Mar; 72(2-3):124-8. PubMed ID: 16172549
    [Abstract] [Full Text] [Related]

  • 52. Intensification of infliximab therapy in Crohn's disease: efficacy and safety.
    M Chaparro, Martínez-Montiel P, Van Domselaar M, Bermejo F, Pérez-Calle JL, Casis B, Román AL, Algaba A, Maté J, Gisbert JP.
    J Crohns Colitis; 2012 Feb; 6(1):62-7. PubMed ID: 22261529
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W, Dejaco C, Feichtenschlager T, Haas T, Kaser A, Miehsler W, Novacek G, Petritsch W, Platzer R, Tilg H, Vogelsang H, Knoflach P, Arbeitsgruppe Chronisch-entzündliche Darmerkrankungen der ÖGGH.
    Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Rapid recovery of a rectovaginal fistula with infliximab in a patient with Crohn's disease.
    Hagiu C, Badea R, Serban A, Petrar S, Andreica V.
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):329-32. PubMed ID: 20922201
    [Abstract] [Full Text] [Related]

  • 58. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
    Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, Millan M, Bailey R, Todoruk D, Cherry R, Teshima CW, Dieleman L, Fedorak RN.
    Aliment Pharmacol Ther; 2010 Nov; 32(9):1129-34. PubMed ID: 20807218
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB, Chapman G, Yau Y, Leong RW.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.